Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Lancet ; 389(10081): 1809-1820, 2017 May 06.
Artigo em Inglês | MEDLINE | ID: mdl-28385352

RESUMO

BACKGROUND: Hot flushes affect 70% of menopausal women and often severely impact physical, psychosocial, sexual, and overall wellbeing. Hormone replacement therapy is effective but is not without risk. Neurokinin B signalling is increased in menopausal women, and has been implicated as an important mediator of hot flushes. METHODS: This phase 2, randomised, double-blind, placebo-controlled, single-centre, crossover trial assessed the effectiveness of an oral neurokinin 3 receptor antagonist (MLE4901) on menopausal hot flushes. Eligible participants were healthy women aged 40-62 years, having seven or more hot flushes in every 24 h of which some were reported as being severe or bothersome, who had not had a menstrual period for at least 12 months, and who had not been taking any medication shown to improve menopausal flushes in the preceding 8 weeks. Participants received 4 weeks of MLE4901 (40 mg, orally, twice daily) and placebo (orally, twice daily) in random order separated by a 2 week washout period. Randomisation was completed by a central computer, and participants were allocated to treatment number in numerical order. The primary outcome was the total number of hot flushes during the final week of both treatment periods. Analyses were by intention to treat and per protocol using generalised linear mixed models and standard crossover analysis. All analyses were prespecified in the study protocol. The trial is registered at ClinicalTrials.gov, number NCT02668185. FINDINGS: 68 women were screened between Feb 3 and Oct 10, 2016, of which 37 were randomly assigned and included in an intention-to-treat analysis. 28 participants completed the trial and were included in a per-protocol analysis. MLE4901 significantly reduced the total weekly number of hot flushes by 45 percentage points (95% CI 22-67) compared with the placebo (intention-to-treat adjusted means: placebo 49·01 [95% CI 40·81-58·56] vs MLE4901 19·35 [15·99-23·42]; adjusted estimate of difference 29·66 [17·39-42·87], p<0·0001). Treatment was well tolerated. Three participants developed a transaminase rise (alanine aminotransferase 4·5-5·9 times the upper limit of normal) with a normal bilirubin 28 days after starting MLE4901, which normalised within 90 days. INTERPRETATION: Treatment with a neurokinin 3 receptor antagonist (MLE4901) could be practice changing as it safely and effectively relieves hot flush symptoms without the need for oestrogen exposure. Larger scale studies of longer duration are now indicated. FUNDING: UK Medical Research Council and National Institute for Health Research.


Assuntos
Fogachos/tratamento farmacológico , Menopausa/fisiologia , Receptores da Neurocinina-3/antagonistas & inibidores , Adulto , Estudos Cross-Over , Método Duplo-Cego , Feminino , Terapia de Reposição Hormonal/efeitos adversos , Terapia de Reposição Hormonal/métodos , Fogachos/etiologia , Humanos , Menopausa/genética , Menopausa/psicologia , Pessoa de Meia-Idade , Receptores da Neurocinina-3/genética , Receptores da Neurocinina-3/uso terapêutico , Resultado do Tratamento
2.
Eur Respir J ; 20(2): 268-73, 2002 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12212954

RESUMO

Gastro-oesophageal reflux is a common clinical disorder associated with a variety of respiratory symptoms, including chronic cough and exacerbation of asthma. In this study, the potential role of acid-induced tachykinin release was examined in guinea pigs and rabbits, by examining the effects of the tachykinin NK1 and NK3 receptors antagonists (SR 140333 and SR 142801, respectively) (1-10 mg x kg(-1)) on plasma protein extravasation induced in airways by hydrochloric acid (HCl) infusion in the oesophagus. Guinea pigs were anaesthetised with urethane, while rabbits were subject to neuroleptoanalgesia with hypnorm. Airway vascular leakage was evaluated by measuring extravasation of Evans blue dye. All animals were pretreated with atropine (1 mg x kg(-1) i.p.), propranolol (1 mg x kg(-1) i.p.), phosphoramidon (2.5 mg x kg(-1) i.v.) and saline or tachykinin receptor antagonists (1-10 mg x kg(-1) i.p.). Infusion of 1 N HCl into the oesophagus led to a three- and five-fold increase in plasma extravasation in the main bronchi and trachea, respectively. This increase was largely prevented by the tachykinin NK1 and NK3 receptor antagonists SR 140333 and SR 142801 (1-10 mg x kg(-1)). These results suggest that protein extravasation in the airways, as induced by intraoesophageal HCl infusion, is mainly dependent on the release of tachykinins, and that both NK1 and NK3 tachykinin receptors are involved. The results suggest that HCl-induced sensory nerve stimulation may act in the periphery on intermediate neurons and/or ganglia where NK3 receptors have been shown to play an important role.


Assuntos
Asma/etiologia , Asma/prevenção & controle , Permeabilidade Capilar/efeitos dos fármacos , Refluxo Gastroesofágico/induzido quimicamente , Refluxo Gastroesofágico/prevenção & controle , Ácido Clorídrico/administração & dosagem , Ácido Clorídrico/efeitos adversos , Antagonistas dos Receptores de Neurocinina-1 , Piperidinas/uso terapêutico , Quinuclidinas/uso terapêutico , Receptores da Neurocinina-1/uso terapêutico , Receptores da Neurocinina-3/antagonistas & inibidores , Receptores da Neurocinina-3/uso terapêutico , Animais , Asma/fisiopatologia , Permeabilidade Capilar/fisiologia , Modelos Animais de Doenças , Esôfago/efeitos dos fármacos , Esôfago/fisiopatologia , Feminino , Refluxo Gastroesofágico/fisiopatologia , Cobaias , Instilação de Medicamentos , Masculino , Piperidinas/farmacologia , Quinuclidinas/farmacologia , Coelhos , Receptores da Neurocinina-1/fisiologia , Receptores da Neurocinina-3/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...